Thus, activation of ML-IAP by BRG1 contributes to the previously observed increase in the resistance of BRG1-expressing SK-MEL-5 melanoma cells to this chemotherapeutic agent (Keenen et al., 2010). The gene discussed is SMARCA4; the disease is melanoma.